Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves' orbitopathy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Sun Young | - |
dc.contributor.author | Choi, Soo Hyun | - |
dc.contributor.author | Kikkawa, Don | - |
dc.contributor.author | Lee, Eun Jig | - |
dc.contributor.author | Yoon, Jin Sook | - |
dc.date.accessioned | 2021-10-05T04:45:13Z | - |
dc.date.available | 2021-10-05T04:45:13Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19984 | - |
dc.description.abstract | Purpose The role of fibroblast growth factor (FGF) in orbital fibroblasts (OFs) is rarely known. In this study, we investigated the effect of FGF10 on fibrosis and the inflammation mechanism of Graves ' orbitopathy (GO). Methods Orbital tissue from GO (n = 15) and non-GO (n = 15) was obtained for this study. The mRNA and protein expression levels of FGF10 and FGF receptor 2b (FGFR2b) in orbital tissue were determined by real-time polymerase chain reaction, western blot analysis, and confocal microscopy. The effects of FGF10 on transforming growth factor (TGF)-beta 1 induced fibrotic proteins and interleukin (IL)-1 beta- or tumor necrosis factor (TNF)-alpha- induced inflammatory proteins were investigated using recombinant human (rh) FGF10 and small interfering (si) RNA transfection against FGF10. Results FGF10 and FGFR2b mRNA expression levels were significantly lower in GO orbital tissues than in non-GO orbital tissues (p = 0.009 and 0.005, respectively). Immunostaining of FGF10 in orbital adipose tissues showed differences in FGF10 expression between GO and control samples. Immunostaining of FGF10 was very weak in the orbital tissues of GO patients. TGF-beta 1-induced fibronectin, collagen I alpha, alpha-smooth muscle actin protein expression in GO OFs was attenuated by rhFGF10 treatment and increased by knockdown of FGF10 via siFGF10 transfection. Similarly, IL-1 beta- or TNF-alpha-induced IL-6, IL-8, and cyclooxygenase-2 protein production in GO OFs was either blocked by rhFGF10 treatment or further upregulated by inhibition of FGF10 via siFGF10 transfection. Conclusions Our data demonstrate that FGF10 has beneficial effects on the inflammatory and fibrotic mechanisms of GO in primary cultured OFs, providing new insights into GO pathology and the discovery of FGF10 as a promising novel therapeutic application for the treatment of GO. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Public Library of Science | - |
dc.title | Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves' orbitopathy | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1371/journal.pone.0255344 | - |
dc.identifier.scopusid | 2-s2.0-85112781401 | - |
dc.identifier.wosid | 000684426400044 | - |
dc.identifier.bibliographicCitation | PLoS ONE, v.16, no.8 | - |
dc.citation.title | PLoS ONE | - |
dc.citation.volume | 16 | - |
dc.citation.number | 8 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | ORBITAL FIBROBLASTS | - |
dc.subject.keywordPlus | PULMONARY-FIBROSIS | - |
dc.subject.keywordPlus | FGF | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | RECEPTOR | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.